Screening Based on Structural and Biological Verification of Stachyose as a PPARγ ‐Modulating Ligand for the Treatment of Non‐Alcoholic Fatty Liver Disease

Documenti analoghi

• The Association Between Dietary Acid Load and Non‐Alcoholic Fatty Liver Disease
  di: Nadia Homayounfar, et al.
  Pubblicazione: (2026)
• Quinoa Improves Non‐Alcoholic Fatty Liver Disease by Regulating the Ras‐ PLD Pathway to Activate Autophagy
  di: Yuelin Zhang, et al.
  Pubblicazione: (2025)
• Integrative Network Pharmacology, Molecular Docking, and In Vitro Insights Into the Mechanism of Finger Citron for Non‐Alcoholic Fatty Liver Disease
  di: Qingpeng Li, et al.
  Pubblicazione: (2026)
• Effects of Canola Oil on Hepatic and Cardiometabolic Markers in Non‐Alcoholic Fatty Liver Disease: A Systematic Review and Meta‐Analysis
  di: Kardelen Büşra Ege Gündüz, et al.
  Pubblicazione: (2026)
• Pachymic Acid Alleviates Non‐Alcoholic Fatty Liver Disease via FGF21 ‐Mediated Inhibition of the p38 MAPK Pathway
  di: Lijuan Nie, et al.
  Pubblicazione: (2026)